Gonapeptyl (Triptorelin Acetate)

Gonapeptyl is indicated for several hormone‑dependent conditions where suppression of gonadotropins is required.

• Advanced prostate cancer: provides medical castration by lowering testosterone levels.
• Endometriosis: alleviates pelvic pain and limits lesion growth through estrogen suppression.
• Uterine fibroids: decreases fibroid volume and menstrual bleeding by reducing ovarian hormone production.
• Central precocious puberty: delays further sexual development by inhibiting pituitary gonadotropin release.
• Assisted reproductive technology: controls timing of follicular development during in‑vitro fertilisation cycles.
• Hormone‑sensitive tumours: used as part of a multidisciplinary approach to reduce tumour‑stimulating hormones.
• Palliative care: may be employed to manage hormone‑related symptoms in certain malignancies.

The pharmacologic action of Gonapeptyl can produce a range of adverse effects, most of which are related to the rapid decline in sex hormones.

Common

• Hot flashes, sweating, and transient headache.
• Decreased libido or erectile dysfunction in men.
• Irregular menstrual bleeding or amenorrhea in women.
• Injection site reactions such as mild pain or erythema.
• Mood changes including depression or anxiety.
• Nausea or gastrointestinal discomfort.

Serious

• Bone mineral density loss leading to osteoporosis with long‑term use.
• Cardiovascular events including hypertension or thromboembolic disorders.
• Severe allergic reactions such as anaphylaxis or angio‑edema.
• Pituitary apoplexy (rare) due to abrupt hormonal shifts.

Before initiating Gonapeptyl therapy, clinicians should evaluate several patient‑specific factors to minimise risks and ensure appropriate use.

• Assess cardiovascular risk, especially in patients with hypertension or a history of thromboembolism.
• Evaluate bone health; consider calcium and vitamin D supplementation for long‑term treatment.
• Review liver and renal function, as dose adjustments may be needed in severe impairment.
• Screen for hypersensitivity to triptorelin acetate or any formulation components.
• Discuss potential impact on fertility and the need for contraceptive measures during treatment.
• Monitor growth and development in children receiving therapy for precocious puberty.
• Consider psychological effects; provide counseling for mood changes or depressive symptoms.

Gonapeptyl may alter the pharmacodynamics or pharmacokinetics of other medicines; certain combinations should be avoided or used with close monitoring.

Avoid

• Concurrent use with other GnRH agonists or antagonists, which can cause excessive hormonal suppression.
• Strong estrogen‑containing therapies that counteract the intended hypo‑estrogenic effect.
• Medications known to prolong the QT interval, increasing cardiac risk when combined with Gonapeptyl.

Use with caution

• Anticoagulants, because injection site bleeding may be enhanced.
• Corticosteroids, as they may affect bone density when combined with long‑term Gonapeptyl.
• Chemotherapeutic agents, requiring coordination to manage overlapping side‑effect profiles.
• Hormone replacement therapy, which may need dose adjustment to maintain desired hormonal levels.